Tyra Biosciences announced initial results from a Phase 2 trial of its cancer drug dabogratinib, revealing significant Grade 3 adverse events in patients. Following this, the company's stock fell nearly 18%. Pomerantz LLP is investigating whether Tyra and its executives engaged in securities fraud or unlawful practices related to the trial data disclosure. Investors affected by the stock drop are advised to contact the law firm for potential class action participation.
Tyra Biosciences is the subject of an investor investigation following adverse trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 19:42 WIB: 74 of 91 health-sector stocks rose today. Notable movers include Twist Bioscience Corp at USD 148.47 with a 3.77% increase, AbCellera Biologics Inc at USD 12.07 up 3.43%, and Ascendis Pharma A/S at USD 239.50 down 3.31%.
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...
Analyst Ivan Feinseth of Tigress Financial raised Amazon's price target from $315 to $385, reflecting a potential 50.8% upside from the current price of $255.37. The upgrade is driven by strong demand for Amazon Web Services (AWS), with much of its 2...
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
